8-K: INmune Bio Advances CORDStrom, XPro1595 Regulatory Paths

INmune Bio announced significant regulatory progress for its CORDStrom RDEB treatment in the UK and XPro1595 for early Alzheimer's Disease with the FDA.

Summary

• Submitted a pre-submission package for CORDStrom to the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
• Anticipate filing a full Marketing Authorization Application (MAA) with MHRA for CORDStrom following receipt of pre-submission feedback, targeted for mid-summer 2026, with subsequent EU and U.S. regulatory submissions to follow in Q4 2026.
• Completed three commercial pilot-scale manufacturing runs for CORDStrom at the CGT Catapult facility, demonstrating consistent product characteristics and readiness for commercial supply.
• CORDStrom has been granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) designation for the treatment of EB in the United States.
• The FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program was reauthorized through September 30, 2029, which could benefit CORDStrom.
• Received official minutes from an End-of-Phase 2 (Type B) meeting with the U.S. Food and Drug Administration (FDA) for XPro1595 in early Alzheimer's Disease (AD).
• The FDA confirmed regulatory alignment on an integrated Phase 2b/3 clinical development strategy for XPro1595 in early AD.
• The FDA raised no objection to the use of Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) as the sole primary efficacy endpoint for the Phase 3 portion of the XPro1595 study.
• The FDA supported the biomarker-driven enrichment strategy for XPro1595, which will enroll patients defined by two or more biomarkers associated with peripheral inflammation and immune-mediated disease risk (hsCRP, ESR, HbA1c, APOE4).
• The XPro1595 Phase 2b portion will enroll approximately 300 participants over a nine-month evaluation period, with the full program expected to enroll approximately 1,000 participants over 18 months.
• An exploratory cohort of non-enriched early Alzheimer's Disease patients (approximately 20% of enrollment) will be included in the XPro1595 trial at the FDA's recommendation.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development due to significant regulatory clarity for two key pipeline assets, XPro1595 and CORDStrom, coupled with favorable legislative action supporting rare disease drug development.

Positives

• Regulatory clarity and alignment with the FDA on an integrated Phase 2b/3 clinical development strategy for XPro1595 in early Alzheimer's Disease.
• FDA's acceptance of CDR-SB as the sole primary efficacy endpoint for the Phase 3 portion of the XPro1595 study, aligning with recently approved AD therapies.
• FDA's support for a biomarker-driven enrichment strategy for XPro1595, validating the company's precision medicine approach.
• Advancement of CORDStrom towards UK marketing authorization with the formal submission of a pre-submission package to the MHRA.
• Successful completion of commercial pilot-scale manufacturing runs for CORDStrom, confirming readiness for commercial supply.
• Reauthorization of the FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program through September 30, 2029, strengthening incentives for CORDStrom, which holds RPD designation.
• Positive safety and efficacy data demonstrated in the MissionEB clinical trial for CORDStrom, showing improvement in itch, pain, skin integrity, and quality of life with excellent tolerability.

Risks

• The company's ability to produce more drug for clinical trials.
• The availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies, and future product commercialization.
• Risks and uncertainties relating to the company's business, research, product development, regulatory approval, marketing, and distribution plans and strategies.
• No assurance that CORDStrom, XPro1595, or INKmune will be approved by the US Food and Drug Administration (FDA), the UK MHRA, or any regulatory body, or that any specific results will be achieved.
• FDA feedback, including statements that the Agency has no objection to aspects of a proposed trial design, does not constitute approval or an agreement that such design will be sufficient to support regulatory approval.

Future Outlook

The company anticipates filing a full Marketing Authorization Application (MAA) with the UK MHRA for CORDStrom following receipt of pre-submission feedback, currently targeted for mid-summer 2026, with subsequent EU and U.S. regulatory submissions to follow in Q4 2026. A planned Biologics License Application (BLA) submission for CORDStrom is targeted for later this year. For XPro1595, the Phase 2b portion of the integrated Phase 2b/3 study is expected to enroll approximately 300 participants over a nine-month evaluation period, designed to validate key efficacy and biomarker assumptions before expanding into the Phase 3 registration segment, which is expected to enroll approximately 1,000 participants over 18 months. The company will provide additional updates on XPro1595 timelines as the protocol is finalized.

Management Comments

• Professor Mark Lowdell, Co-Founder & CSO of INmune Bio: "Meeting the deadline for our pre-submission for CORDStrom marks a critical milestone, building upon the positive safety and efficacy data demonstrated in the MissionEB clinical trial and the successful transition into our commercial manufacturing facility in Stevenage, UK."
• Professor Mark Lowdell: "We are committed to delivering the first systemic therapy for RDEB patients and families, starting in the UK, and look forward to feedback from the MHRA in the hope of accelerating the regulatory and commercial pathway to approval."
• CEO David Moss: "We welcome Congresss bipartisan action to extend the Rare Pediatric Disease PRV program. This reauthorization removes a major uncertainty and strengthens the incentive landscape for advancing innovative treatments for children with devastating rare conditions."
• CEO David Moss: "With our planned BLA submission targeted for later this year, we are well-positioned to potentially benefit from this important incentive as we work to bring CORDStrom to RDEB patients who urgently need new options."
• CJ Barnum, PhD, Vice President of Neuroscience at INmune Bio: "The FDAs feedback on our enrichment-led design, primary endpoint, and integrated Phase 2b/3 structure validates our scientific and clinical strategy and provides a clearly defined regulatory path to advancing XPro1595 into a registration-intent program in early Alzheimers disease."
• CJ Barnum, PhD: "Our Phase 2 MINDFuL trial provided important insights into cognitive and biomarker measures in the enriched population. These findings informed the statistical assumptions and powering strategy for the Phase 3 portion of the program."
• CEO David Moss: "Our End-of-Phase 2 interaction with the FDA reflects alignment between our proposed development strategy and the Agencys expectations for late-stage Alzheimers programs."
• CEO David Moss: "XPro1595 represents a differentiated approach to Alzheimers disease, based on precision patient selection and selective immune modulation, with a favorable safety profile that included zero cases of ARIA in our Phase 2 study."

Industry Context

StockSavvy.ai notes that the reauthorization of the FDA's Rare Pediatric Disease PRV program provides a significant incentive for companies developing treatments for rare pediatric conditions, aligning with broader industry efforts to address unmet medical needs in this area. The FDA's alignment on an integrated Phase 2b/3 pathway for XPro1595 in Alzheimer's disease, particularly with a biomarker-driven enrichment strategy and CDR-SB as the primary endpoint, reflects a growing trend in neurodegenerative disease research towards precision medicine and validated outcome measures, similar to approaches seen with other recently approved AD therapies.

Comparison to Industry Standards

• CORDStrom for RDEB: Currently, there are no approved systemic therapies for RDEB, with options limited to topical wound treatments. CORDStrom aims to be the first systemic therapy, positioning INmune Bio at the forefront of RDEB treatment development.
• XPro1595 for Alzheimer's Disease: The FDA's acceptance of CDR-SB as the sole primary efficacy endpoint for Phase 3 aligns with the primary endpoint used in recently approved Alzheimer's disease therapies, such as those from Biogen/Eisai (Leqembi) and Eli Lilly (Donanemab, pending approval), indicating a standard and accepted measure for registrational programs in AD. The biomarker-driven enrichment strategy for XPro1595 is consistent with the precision medicine approach increasingly adopted in AD research to target specific patient populations.

Stakeholder Impact

• Shareholders: Potential for increased value due to clearer regulatory pathways and incentives for key drug candidates.
• Patients (RDEB): Hope for the first systemic therapy to address a devastating genetic disorder, potentially improving quality of life, pain, itch, and skin integrity.
• Patients (Early Alzheimer's Disease): Potential for a new, differentiated treatment approach based on precision patient selection and selective immune modulation, offering a favorable safety profile.
• Regulatory Authorities (MHRA, FDA): Engagement in the regulatory process for novel therapies for unmet medical needs.

Next Steps

• Receive feedback from UK MHRA on CORDStrom pre-submission package (targeted mid-summer 2026).
• File full Marketing Authorization Application (MAA) with MHRA for CORDStrom (following feedback, targeted mid-summer 2026).
• Subsequent EU and U.S. regulatory submissions for CORDStrom (targeted Q4 2026).
• Planned BLA submission for CORDStrom (targeted later this year).
• INmune Bio to incorporate FDA feedback into final XPro1595 Phase 2b/3 protocol.
• Submit XPro1595 Phase 2b/3 protocol to FDA for review.
• Provide additional updates on XPro1595 timelines as protocol is finalized.
• Enroll approximately 300 participants in XPro1595 Phase 2b over nine months.
• Expand XPro1595 program to approximately 1,000 participants for Phase 3 over 18 months.

Key Dates

Recommendation

The company has achieved significant regulatory milestones for two of its key pipeline assets, CORDStrom and XPro1595. For CORDStrom, the pre-submission to the UK MHRA and successful manufacturing runs, coupled with the reauthorization of the Rare Pediatric Disease PRV program, significantly de-risk its path to market for a disease with no current systemic therapies. For XPro1595, the FDA's alignment on an integrated Phase 2b/3 pathway, acceptance of CDR-SB as the primary endpoint, and support for a biomarker-driven enrichment strategy provide a clear and validated path forward for a differentiated Alzheimer's treatment. These developments substantially increase the probability of successful clinical development and eventual commercialization, making the stock highly attractive for long-term investors.

Keywords

Biotechnology, Clinical-stage, Inflammation, Immunology, Recessive Dystrophic Epidermolysis Bullosa, RDEB, Alzheimer's Disease, AD, CORDStrom, XPro1595, MHRA, FDA, Regulatory Approval, Rare Disease, Orphan Drug, Priority Review Voucher, PRV, Precision Medicine, Neuroinflammation